Vision

Our core vision is to “Invest and invent in Taiwan and patent globally”. We develop unmet medical solutions to battle leukemia, other cancers, and autoimmune disease and offer patients with better medical options for patients around the world.

Mission

Develop, manufacture and market innovative chemical anti-cancer drugs to benefit cancer patients in Taiwan and around the world. Enhance company presence globally and maximize shareholder value.

Expectation

BoYen Therapeutics aims to be the first and only Taiwan new drug company that achieves sales of 100 million US dollars for single new drug.

Development Strategy

• Continue prodrug developments and supply unmet medical needs.
• At the most appropriate time, license out clinical stage drug candidates, acquire signing bonus, royalties and milestone payments.
• We welcome capable strategic partners to collaborate and develop / commercialize our drugs candidates. Merger and Acquisition(M&A) is also an option.
• BoYen Therapeutics plans to public issued in late 2022 and then publicly traded on OTC.
• We also consider going for IPO on the U.S. NASDAQ and / or other open markets.